PLx Pharma Winddown Corp.

2018 Q1 Form 10-Q Financial Statement

#000143774918009524 Filed on May 11, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.42M $12.41M
YoY Change 64.54% -54.29%
Cash & Equivalents $20.42M $425.8K
Short-Term Investments
Other Short-Term Assets $1.440M $80.00K
YoY Change 1700.0% -27.27%
Inventory
Prepaid Expenses $269.0K $83.02K
Receivables $80.00K
Other Receivables $0.00
Total Short-Term Assets $21.94M $12.53M
YoY Change 75.01% -54.02%
LONG-TERM ASSETS
Property, Plant & Equipment $1.182M
YoY Change
Goodwill $2.061M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $70.00K $2.057M
YoY Change -96.6% 2185.14%
Total Long-Term Assets $3.311M $2.057M
YoY Change 60.98% 2185.14%
TOTAL ASSETS
Total Short-Term Assets $21.94M $12.53M
Total Long-Term Assets $3.311M $2.057M
Total Assets $25.25M $14.59M
YoY Change 73.03% -46.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $820.0K $60.00K
YoY Change 1266.67% 50.0%
Accrued Expenses $420.0K $400.0K
YoY Change 5.0% -51.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.245M $460.0K
YoY Change 170.65% -47.13%
LONG-TERM LIABILITIES
Long-Term Debt $7.003M $0.00
YoY Change
Other Long-Term Liabilities $137.0K
YoY Change
Total Long-Term Liabilities $7.140M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.245M $460.0K
Total Long-Term Liabilities $7.140M $0.00
Total Liabilities $15.35M $462.1K
YoY Change 3221.01% -46.88%
SHAREHOLDERS EQUITY
Retained Earnings -$62.35M -$63.91M
YoY Change -2.44%
Common Stock $72.25M $78.04M
YoY Change -7.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.899M $14.13M
YoY Change
Total Liabilities & Shareholders Equity $25.25M $14.59M
YoY Change 73.03% -46.65%

Cashflow Statement

Concept 2018 Q1 2017 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 plxp Accrued Bonuses And Severances Current
AccruedBonusesAndSeverancesCurrent
307689
CY2017Q4 plxp Accrued Bonuses And Severances Current
AccruedBonusesAndSeverancesCurrent
849703
CY2018Q1 plxp Built In Gains Tax Liability
BuiltInGainsTaxLiability
0
CY2018Q1 plxp Contract Manufacturing Deposits Current
ContractManufacturingDepositsCurrent
1168687
CY2017Q4 plxp Contract Manufacturing Deposits Current
ContractManufacturingDepositsCurrent
715603
CY2018Q1 plxp Increase Decrease In Bonuses And Severances
IncreaseDecreaseInBonusesAndSeverances
-542014
CY2017Q1 plxp Increase Decrease In Bonuses And Severances
IncreaseDecreaseInBonusesAndSeverances
CY2018Q1 plxp Increase Decrease In Interest Payable Net Excluding Related Parties
IncreaseDecreaseInInterestPayableNetExcludingRelatedParties
55543
CY2017Q1 plxp Increase Decrease In Interest Payable Net Excluding Related Parties
IncreaseDecreaseInInterestPayableNetExcludingRelatedParties
70260
CY2018Q1 plxp Increase Decrease In Interest Payable To Related Parties Net
IncreaseDecreaseInInterestPayableToRelatedPartiesNet
CY2017Q1 plxp Increase Decrease In Interest Payable To Related Parties Net
IncreaseDecreaseInInterestPayableToRelatedPartiesNet
11297
CY2018Q1 plxp Increase Decrease In Research Services Deposits
IncreaseDecreaseInResearchServicesDeposits
453084
CY2017Q1 plxp Increase Decrease In Research Services Deposits
IncreaseDecreaseInResearchServicesDeposits
670000
CY2018Q1 plxp Interest Payable Excluding Related Parties Current
InterestPayableExcludingRelatedPartiesCurrent
55418
CY2017Q4 plxp Interest Payable Excluding Related Parties Current
InterestPayableExcludingRelatedPartiesCurrent
54219
CY2018Q1 plxp Interest Payable Noncurrent
InterestPayableNoncurrent
144061
CY2017Q4 plxp Interest Payable Noncurrent
InterestPayableNoncurrent
89717
CY2018Q1 plxp Proceeds From Convertible Debt Excluding Related Parties
ProceedsFromConvertibleDebtExcludingRelatedParties
CY2017Q1 plxp Proceeds From Convertible Debt Excluding Related Parties
ProceedsFromConvertibleDebtExcludingRelatedParties
460000
plxp Proceeds From Convertible Debt Related Parties
ProceedsFromConvertibleDebtRelatedParties
588300
CY2018Q1 plxp Proceeds From Convertible Debt Related Parties
ProceedsFromConvertibleDebtRelatedParties
CY2017Q1 plxp Proceeds From Convertible Debt Related Parties
ProceedsFromConvertibleDebtRelatedParties
108300
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2018Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2018Q1 plxp Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
CY2018Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
821931
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
852155
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
72243918
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
71939917
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
281505
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
187909
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3878802
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
930762
CY2017Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q1 us-gaap Assets
Assets
25246570
CY2017Q4 us-gaap Assets
Assets
28848573
CY2018Q1 us-gaap Assets Current
AssetsCurrent
21935898
CY2017Q4 us-gaap Assets Current
AssetsCurrent
25689962
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8364
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24404368
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59335
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20418155
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
425785
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3986213
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
366450
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8726198
CY2018Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
20400000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8722823
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8726198
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8722823
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
8727
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
8723
CY2017Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
920000
CY2018Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
4064
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
4064
CY2018Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
67714
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
67714
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34068
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
314
CY2018Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6818268
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
15242915
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y255D
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1100000
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8424647
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2018Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2017Q4 us-gaap Goodwill
Goodwill
2061022
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2240000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1217071
CY2018Q1 us-gaap Goodwill
Goodwill
2061022
CY2017Q4 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
2300000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4978592
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1426967
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
73470
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-114702
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
56643
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1250
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
217251
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
173335
CY2018Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-4371
CY2017Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-31204
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15465
CY2018Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
275354
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
81557
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
158698
CY2017Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2018Q1 us-gaap Inventory Net
InventoryNet
CY2017Q4 us-gaap Inventory Net
InventoryNet
246374
CY2018Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
743170
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
319736
CY2018Q1 us-gaap Inventory Write Down
InventoryWriteDown
463625
CY2017Q1 us-gaap Inventory Write Down
InventoryWriteDown
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
66923
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
CY2018Q1 us-gaap Liabilities
Liabilities
15347581
CY2017Q4 us-gaap Liabilities
Liabilities
24232181
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25246570
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28848573
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1245010
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1815691
CY2018Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7003264
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6942151
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2568300
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-267323
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72411
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3718890
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2129439
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
4978592
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-1426967
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8216171
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-81557
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
3319036
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1345410
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3237579
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1345410
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1100841
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
258170
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
190874
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
301993
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
349804
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
32769
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
14721
CY2018Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
59972
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
59614
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
136978
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
141707
CY2018Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
61113
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
267323
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
72411
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
268965
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
300169
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2346000
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18200000
CY2018Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
CY2017Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2000000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1181936
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1029875
CY2018Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
76027
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
19384
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1166709
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1174209
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.54
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1079036
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
128339
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.47
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.29
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62353656
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67332248
CY2017Q1 us-gaap Revenues
Revenues
0
CY2018Q1 us-gaap Revenues
Revenues
81457
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
281505
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
187909
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
888124
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
21.71
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7500
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
90097
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y73D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y292D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y219D
CY2018Q1 us-gaap Stock Issued1
StockIssued1
22500
CY2017Q1 us-gaap Stock Issued1
StockIssued1
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
9898989
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
4616392
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, determining the fair value of tangible and intangible assets and liabilities acquired in business combinations, the fair value of warrant liabilities, share-based compensation, our allowance for inventory obsolescence, our allowance for doubtful accounts, contingent liabilities, the fair value and depreciable lives of long-lived assets, and deferred taxes and the associated valuation allowance. Actual results could differ from those estimates.</div></div></div>
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8725038
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4383433
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8725038
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4383433

Files In Submission

Name View Source Status
0001437749-18-009524-index-headers.html Edgar Link pending
0001437749-18-009524-index.html Edgar Link pending
0001437749-18-009524.txt Edgar Link pending
0001437749-18-009524-xbrl.zip Edgar Link pending
ex_112272.htm Edgar Link pending
ex_112273.htm Edgar Link pending
ex_112274.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img.gif Edgar Link pending
plxp-20180331.xml Edgar Link completed
plxp-20180331.xsd Edgar Link pending
plxp-20180331_cal.xml Edgar Link unprocessable
plxp-20180331_def.xml Edgar Link unprocessable
plxp-20180331_lab.xml Edgar Link unprocessable
plxp-20180331_pre.xml Edgar Link unprocessable
plxp20180331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending